** Shares of Zevra Therapeutics ZVRA.O rise 5.14% to $7.77
** Zevra says it enters agreement to sell its rare pediatric disease Priority Review Voucher $(PRV.UK)$ for $150 million
** The U.S. FDA granted the company PRV in September 2024 after approval of its drug Miplyffa
** Miplyffa is indicated for use in combination with co's other genetic disorder drug, miglustat, to treat rare neurological condition passed genetically in adult and pediatric patients 2 years of age and older
** PRV holders can benefit from an expedited six-month review of a new drug application for any disease by the FDA
** ZVRA has fallen 7.19% YTD
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.